TGA / PMDA / NMPA · Asia-Pacific
neuroprotective — TGA / PMDA / NMPA regulatory status
neuroprotective regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 2 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| DEXMEDETOMIDINE , 18F-DPA-714 | Phase 3 | PARItec | 2024-511898-30-00 |
| Intra-arterial administration of neuroprotective agents | Unknown | Hui-Sheng Chen | NCT04664946 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 11974988 | Neuroprotective compositions and methods of using the same | US |
| 11970521 | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives | US |
| 11872312 | Neuroprotective liposome compositions and methods for treatment of stroke | US |
| 11471502 | Neuroprotective peptide | US |
| 11414379 | SPAK kinase inhibitors as neuroprotective agents | US |
| 11147795 | Neuroprotective compounds and methods of use | US |
| 10995061 | SPAK kinase inhibitors as neuroprotective agents | US |
| 10973764 | Neuroprotective liposome compositions and methods for treatment of stroke | US |
| 10369103 | Neuroprotective liposome compositions and methods for treatment of stroke | US |
| 9902713 | Neuroprotective compounds and use thereof | US |
| 9645139 | Neuroprotective chemicals and methods for identifying and using same | US |
| 9243281 | Neuroprotective chemicals and methods for identifying and using same | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of neuroprotective?
neuroprotective currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get neuroprotective regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to neuroprotective?
This spoke lists 2 published programs associated with neuroprotective in our pipeline index.